Valerio Therapeutics: Gilles Besin Appointed CEO Effective July 1, 2026

A Profile from Major Biotech Successes

Gilles Besin brings over twenty years of experience in molecule discovery, immunology, and RNA-based drugs. He comes from Orbital Therapeutics in Cambridge, Massachusetts, where he served as Chief Scientific Officer before the company was acquired by Bristol Myers Squibb in December 2025 for $1.5 billion. Following the acquisition, he joined Bristol Myers Squibb as the head of RNA and in vivo CAR-T cells, as well as the director of the Cambridge Kendall Square site. Prior to Orbital, Besin held the positions of Vice President and Head of Discovery Research at Affinivax, where he played a key role in the company's acquisition by GlaxoSmithKline in 2022 for $3.3 billion. He has also held R&D responsibilities at In-Cell-Art, Moderna, and various academic and translational research institutions.

Miara and Barouky Step Down, Continuity Ensured

Julien Miara and Antoine Barouky will step down from their respective positions on June 30, 2026. Under their leadership, Valerio Therapeutics underwent a significant transformation of its operational model, refocusing its activities on high-potential opportunities and laying the groundwork for its next growth phase. Both will remain on the board of directors and will support Besin to ensure a smooth transition and the continued execution of the group's strategic priorities.

Approval of All Resolutions at the General Meeting

The general meeting of shareholders held on Tuesday, June 16, 2026, approved all resolutions recommended by the board of directors. This approval includes the reappointment of Antonin de Fougerolles and Financière de la Montagne, as well as the appointment of new board members Eric Vivier, Wael Jdey, and Gilles Besin.